104 related articles for article (PubMed ID: 24022057)
1. Cervical cancer rates after the transition from annual Pap to 3-year HPV and Pap.
Dinkelspiel H; Fetterman B; Poitras N; Kinney W; Cox JT; Lorey T; Castle PE
J Low Genit Tract Dis; 2014 Jan; 18(1):57-60. PubMed ID: 24022057
[TBL] [Abstract][Full Text] [Related]
2. Cervical cancer screening with both human papillomavirus and Papanicolaou testing vs Papanicolaou testing alone: what screening intervals are physicians recommending?
Saraiya M; Berkowitz Z; Yabroff KR; Wideroff L; Kobrin S; Benard V
Arch Intern Med; 2010 Jun; 170(11):977-85. PubMed ID: 20548011
[TBL] [Abstract][Full Text] [Related]
3. History of high-risk HPV and Pap test results in a large cohort of patients with invasive cervical carcinoma: experience from the largest women's hospital in China.
Tao X; Griffith CC; Zhou X; Wang Z; Yan Y; Li Z; Zhao C
Cancer Cytopathol; 2015 Jul; 123(7):421-7. PubMed ID: 25955972
[TBL] [Abstract][Full Text] [Related]
4. Comparison of cervical cancer screening results among 256,648 women in multiple clinical practices.
Blatt AJ; Kennedy R; Luff RD; Austin RM; Rabin DS
Cancer Cytopathol; 2015 May; 123(5):282-8. PubMed ID: 25864682
[TBL] [Abstract][Full Text] [Related]
5. Prior high-risk HPV testing and Pap test results for 427 invasive cervical cancers in China's largest CAP-certified laboratory.
Zheng B; Li Z; Griffith CC; Yan S; Chen C; Ding X; Liang X; Yang H; Zhao C
Cancer Cytopathol; 2015 Jul; 123(7):428-34. PubMed ID: 25954852
[TBL] [Abstract][Full Text] [Related]
6. Reassurance against future risk of precancer and cancer conferred by a negative human papillomavirus test.
Gage JC; Schiffman M; Katki HA; Castle PE; Fetterman B; Wentzensen N; Poitras NE; Lorey T; Cheung LC; Kinney WK
J Natl Cancer Inst; 2014 Aug; 106(8):. PubMed ID: 25038467
[TBL] [Abstract][Full Text] [Related]
7. Relative Performance of HPV and Cytology Components of Cotesting in Cervical Screening.
Schiffman M; Kinney WK; Cheung LC; Gage JC; Fetterman B; Poitras NE; Lorey TS; Wentzensen N; Befano B; Schussler J; Katki HA; Castle PE
J Natl Cancer Inst; 2018 May; 110(5):501-508. PubMed ID: 29145648
[TBL] [Abstract][Full Text] [Related]
8. Screening test results associated with cancer diagnoses in 287 women with cervical squamous cell carcinoma.
Li Z; Austin RM; Guo M; Zhao C
Arch Pathol Lab Med; 2012 Dec; 136(12):1533-40. PubMed ID: 22900617
[TBL] [Abstract][Full Text] [Related]
9. Trends Over Time in Pap and Pap-HPV Cotesting for Cervical Cancer Screening.
MacLaughlin KL; Jacobson RM; Radecki Breitkopf C; Wilson PM; Jacobson DJ; Fan C; St Sauver JL; Rutten LJF
J Womens Health (Larchmt); 2019 Feb; 28(2):244-249. PubMed ID: 30614380
[TBL] [Abstract][Full Text] [Related]
10. Impact of pap test compliance and cervical cancer screening intervals on human papillomavirus vaccine acceptance.
Ferris DG; Waller J; Dickinson A; McCracken C; Goebel A
J Low Genit Tract Dis; 2012 Jan; 16(1):39-44. PubMed ID: 22126831
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the clinical performance of high-risk human papillomavirus testing for primary screening: a retrospective review of the Southern California Permanente Medical Group experience.
Lonky NM; Mahdavi A; Wolde-Tsadik G; Bajamundi K; Felix JC
J Low Genit Tract Dis; 2010 Jul; 14(3):200-5. PubMed ID: 20592555
[TBL] [Abstract][Full Text] [Related]
12. Clinical practice. Cervical-cancer screening with human papillomavirus and cytologic cotesting.
Schiffman M; Solomon D
N Engl J Med; 2013 Dec; 369(24):2324-31. PubMed ID: 24328466
[No Abstract] [Full Text] [Related]
13. Cervical screening test results associated with 265 histopathologic diagnoses of cervical glandular neoplasia.
Zhao C; Li Z; Austin RM
Am J Clin Pathol; 2013 Jul; 140(1):47-54. PubMed ID: 23765533
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the Impact of Human Papillomavirus DNA Self-sampling on the Uptake of Cervical Cancer Screening.
Wong EL; Chan PK; Chor JS; Cheung AW; Huang F; Wong SY
Cancer Nurs; 2016; 39(1):E1-E11. PubMed ID: 25730587
[TBL] [Abstract][Full Text] [Related]
15. Uptake of HPV testing and extended cervical cancer screening intervals following cytology alone and Pap/HPV cotesting in women aged 30-65 years.
Silver MI; Rositch AF; Phelan-Emrick DF; Gravitt PE
Cancer Causes Control; 2018 Jan; 29(1):43-50. PubMed ID: 29124542
[TBL] [Abstract][Full Text] [Related]
16. Five-year experience of human papillomavirus DNA and Papanicolaou test cotesting.
Castle PE; Fetterman B; Poitras N; Lorey T; Shaber R; Kinney W
Obstet Gynecol; 2009 Mar; 113(3):595-600. PubMed ID: 19300322
[TBL] [Abstract][Full Text] [Related]
17. Use of electronic health record-based tools to improve appropriate use of the human papillomavirus test in adult women.
Broach V; Day L; Barenberg B; Huang S; Kenton K; White P
J Low Genit Tract Dis; 2014 Jan; 18(1):26-30. PubMed ID: 23959296
[TBL] [Abstract][Full Text] [Related]
18. Cervical cancer incidence in British Columbia: Predicting effects of changes from Pap to human papillomavirus screening and of changes in screening participation.
Coldman A; van Niekerk D; Smith L; Ogilvie G
J Med Screen; 2017 Dec; 24(4):195-200. PubMed ID: 27810984
[TBL] [Abstract][Full Text] [Related]
19. Practice patterns in cervical cancer screening and human papillomavirus testing.
Tatsas AD; Phelan DF; Gravitt PE; Boitnott JK; Clark DP
Am J Clin Pathol; 2012 Aug; 138(2):223-9. PubMed ID: 22904133
[TBL] [Abstract][Full Text] [Related]
20. Adherence patterns to extended cervical screening intervals in women undergoing human papillomavirus (HPV) and cytology cotesting.
Rendle KA; Schiffman M; Cheung LC; Kinney WK; Fetterman B; Poitras NE; Lorey T; Castle PE
Prev Med; 2018 Apr; 109():44-50. PubMed ID: 29288782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
